Axm Pharma, Inc. Receives Approval From Chinese Food And Drug Administration To Market New Treatment For Diabetes; Drug Demonstrates Efficacy In Clinical Activities

Published: Dec 22, 2005

LAS VEGAS--(BUSINESS WIRE)--Dec. 23, 2005--AXM Pharma, Inc. (Amex: AXJ), a manufacturer of proprietary and generic pharmaceutical and nutraceutical products for the Chinese and other Asian markets, announced today that its wholly-owned subsidiary AXM Pharma, (Shenyang) Inc., has received approval from the Chinese Food and Drug Administration to sell Glucostrim(TM) (Qiyao) Anti-diabetes Capsules in China, its new treatment for diabetes. The Company received a New Drug Certificate, allowing it to produce and sell the product commencing in March.

Back to news